ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Almac Sciences has completed an expansion of active pharmaceutical ingredient production in Craigavon, Northern Ireland, that adds continuous-flow manufacturing capabilities. The company also plans to implement continuous-flow manufacturing at its Arran Chemical facility in Athlone, Ireland. Meanwhile, Almac has added a second high-throughput peptide line at its Edinburgh, Scotland, facility, where it manufactures neoantigen-derived peptides for use in patient-specific cancer vaccines.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X